# Carlsmed (NASDAQ: CARL) — Investment Analysis

## Company & Research Metadata

- **Company:** Carlsmed, Inc.
- **Ticker:** CARL
- **Exchange:** Nasdaq
- **Sector / Industry:** Health Care / Medical Devices (personalized spine implants)
- **Template version:** 2.7
- **Research date:** 2026-10-21 (comparison refresh; fundamental review preserved from 2026-10-17)
- **Valuation / score price snapshot:** $14.40 — 2026-11-03 regular-session close, America/New_York
- **Tracking tier:** On the Radar
- **Owned:** No
- **Primary operating period reviewed:** Q2 2026 and H1 2026
- **Historical period reviewed:** FY 2024–FY 2025 and H1 2026
- **Latest investor presentation reviewed:** Not separately identified in initial review
- **Latest earnings call reviewed:** Q2 2026, 2026-08-05
- **Latest post-earnings management commentary reviewed:** 2026-09-28 CFO appointment and guidance reaffirmation; 2026-10-14 product launch

Carlsmed is an emerging medical technology company attempting to change how spinal fusion surgeries are performed. Rather than relying exclusively on standard-sized implants, it uses AI-assisted planning and patient-specific implants designed around each person's spinal anatomy.

The investment thesis is compelling: **If personalized spinal surgery becomes a widely adopted standard of care, Carlsmed could capture a meaningful position in a large market while benefiting from unusually high gross margins.**

Its financial results show that adoption is accelerating, but the company remains unprofitable, and the durability of its competitive advantage is still unproven.

- **Price snapshot date:** 2026-11-03

- **Price snapshot time / timezone:** Regular-session close, America/New_York (including exchange half-days)
- **Competitor / analyst-Q&A audit:** 2026-10-28; original operating, price and valuation snapshots retained.

## What's Changed Since Previous Review

**Current Review:** 2026-10-28

**Previous Review:** 2026-10-21 (comparison refresh; fundamental review preserved from 2026-10-17)

**Update Trigger:** Competitor relevance and analyst-Q&A correction

| Area | Previous View | Current View | Investment Impact |
|---|---|---|---|
| Competition | Preceding operating and comparable-company classifications | Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors | Corrects the competitive comparison; does not by itself re-underwrite the valuation |
| Analyst questions | Prior source-linked Q&A summaries | Complete questions and sentence-form management answers; all 5 existing rows retained | Improves readability while preserving the recorded exchange meaning |
| Valuation and scores | Approved operating/price snapshots, scenarios, scores and decisions | Preserved | No price refresh, rerank or change to valuation assumptions in this correction pass |

**Thesis:** No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

## Investment Snapshot

| Metric | Current View |
|---|---|
| Price Snapshot | $14.40 — 2026-11-03 regular-session close, America/New_York |
| Rating / Zone Status | Hold / Watch |
| Bear / Base / Bull Fair Value | $4.52 / $16.23 / $34.11 |
| Scenario Probabilities | 30% / 50% / 20% |
| Probability-Weighted Fair Value | $16.29 |
| Probability-Weighted Expected Return | +13.1% |
| Bear-Case Return | -68.6% |
| Strong Buy Zone | ≤ $4.97 |
| Buy Zone | >$4.97–$13.03 |
| Avoid Chasing Above | > $18.10 |
| Quality Score / Tier | 64.8 / Tier C |
| Opportunity Score / Rank | 51.7 / #41 of 76 |
| Risk Level | High |
| Tracking / Ownership | On the Radar / Not Owned |

**Decision rationale:** Carlsmed has an attractive growth profile, a potentially valuable technology platform, and improving gross margins. However, the upside in my probability-weighted valuation is insufficient compensation for the considerable downside if adoption or profitability disappoints. At $13.41, I would monitor rather than initiate a full position.

## Investment Thesis

The fundamental question is whether Carlsmed can turn personalized spinal fusion from a premium niche product into a mainstream surgical platform.

Traditional spinal implants come in standardized dimensions. Surgeons choose from available shapes and sizes, using their experience to obtain the desired alignment. Carlsmed reverses part of that process: surgeons first plan the desired correction using patient imaging and software, then order implants manufactured to the patient's anatomy.

If this approach consistently reduces complications, hospitals could accept the product's higher cost because fewer revision surgeries would improve overall treatment economics. Surgeons might also become repeat users, supporting revenue growth without constantly rebuilding the customer base.

### What the Market May Be Mispricing

The most important potential mispricings are threefold:

1. The market may underestimate how improved Medicare reimbursement can ease hospital adoption.
2. Carlsmed's digital manufacturing system may ultimately produce much stronger operating leverage than its current losses suggest.
3. The market may be overestimating the durability of Carlsmed's technological lead in a category where much larger implant companies can compete.

I favor the first two elements of the thesis, but the third prevents me from assigning the business a durable moat today.

## Business Overview

Carlsmed primarily sells its *aprevo* platform for personalized spinal fusion procedures in U.S. hospitals and surgical centers.

| Product / Platform | Role | Investment Relevance |
|---|---|---|
| aprevo Lumbar | Personalized interbody implants for lumbar fusion | Core revenue contributor |
| aprevo Cervical | Personalized implants for cervical fusion | Newer growth opportunity; about 10% of Q2 revenue |
| myaprevo | Digital surgical planning and workflow ecosystem | Supports surgeon engagement and customization |
| aprevo Bi-lateral Posterior | Expands lumbar procedures accessible to its platform | Commercially launched October 14, 2026 |
| corra Cervical Plating | Personalized cervical plating system | Planned broader launch in Q4 2026; may increase revenue per case |

Carlsmed receives revenue when its implants are used in a surgical procedure. Hospitals are typically the purchasing customers, while surgeons are the primary product decision-makers. Its go-to-market model includes a direct commercial organization and independent sales agents.

Importantly, this is **not recurring software revenue**. Every new procedure generates a sale, and the opportunity to retain a surgeon depends on continued confidence in the platform, patient outcomes, hospital authorization, and the economics of each case.

Carlsmed uses third-party manufacturing partners and software-enabled production workflows rather than maintaining the extensive standardized implant inventory typical of some established device companies. Its manufacturing lead times have reportedly fallen to less than a week. That could reduce working capital needs as the business scales, although dependence on manufacturing partners creates execution risk.

### Business Takeaway

The model is attractive because it combines customized medical devices with a relatively asset-light supply chain. But Carlsmed must establish itself through hospital approvals and surgeon relationships before it can benefit from the efficiencies of scale.

## Industry, TAM & Market Share

Management estimates the U.S. addressable opportunity at approximately $13.4 billion for lumbar implants and $6 billion for cervical implants, totaling **$19.4 billion**.

These estimates reflect approximate procedure counts multiplied by the company's average revenue per procedure. They represent the theoretical value of broad adoption rather than the immediate market Carlsmed can realistically capture.

Using the midpoint of 2026 guidance, Carlsmed's expected $76 million in revenue equals approximately 0.39% of that theoretical opportunity. This is a penetration proxy, **not a verified market-share figure**, because the market estimate uses Carlsmed-specific pricing and encompasses procedures that may not be commercially accessible to it.

The broader spinal fusion market is relatively mature. Carlsmed's opportunity is therefore primarily share gains and the development of new procedure categories, not rapid expansion of total spinal surgery volumes.

### Market-Share Analysis

A consistent, comparable market-share dataset for personalized implants and the relevant conventional alternatives is not publicly available.

#### Competitive Scale / Position

| Company / Platform | Primary Position | Relative Scale | Growth Direction | Investment Relevance |
|---|---|---|---|---|
| Carlsmed | Specialist in personalized spinal fusion implants | Small emerging company | Rapid growth | Product-specific share gains |
| Globus Medical | Broad spine implants, enabling technology and robotics | Multi-billion-dollar revenue scale | Established incumbent | Large-scale competing platform |
| Medtronic | Broad spinal implants, navigation and surgical technology | Global diversified medtech | Established incumbent | Distribution and ecosystem competitor |
| DeGen Medical | Patient-specific implants and spinal devices | Private; scale not disclosed | Expanding product offering | Direct customized implant competition |

An additional industry catalyst is the CMS fiscal-year 2027 inpatient payment rule, effective October 1, 2026. It introduced new diagnosis-related groups benefiting qualifying personalized lumbar procedures. Better hospital reimbursement could make the economics more attractive, but it does not automatically raise Carlsmed's selling prices or ensure coverage at every hospital.

### Industry Takeaway

The market is sufficiently large to support substantial growth even at low penetration. The key variables are access to hospitals, surgeon adoption, competitive differentiation, and whether reimbursement improvements translate into higher procedural volumes.

## Customer Economics

The most useful operating metric is revenue per procedure.

| Metric | Q2 2026 |
|---|---:|
| Lumbar average revenue per procedure | Approximately $29,000 |
| Cervical average revenue per procedure | Approximately $18,000 |
| Cervical share of revenue | Approximately 10% |
| Trained surgeon users | More than 60% YoY growth |
| Gross margin | 76.8% |
| Sales and marketing / revenue | Approximately 63% |

The pricing is attractive, and new product introductions should allow the company to capture a greater share of spending per surgeon. Cervical is especially interesting because it is marketed to an overlapping surgeon population rather than requiring an entirely new sales channel.

However, the headline gross margin requires careful interpretation. Independent sales-agent fees are recorded under sales and marketing expenses rather than cost of goods sold. In Q2, Carlsmed generated $14.5 million in gross profit but spent $11.9 million on sales and marketing.

That does not mean selling costs consume the full difference on each incremental case; much of the expense supports building the business. It does mean the 76.8% gross margin is not equivalent to a 76.8% economic contribution margin.

The company does not disclose sufficient surgeon retention, procedure-frequency, or customer-acquisition-cost information to calculate reliable lifetime customer economics. Growth in trained surgeons is encouraging, but increases in utilization per active surgeon will be more revealing over time.

### Customer-Economics Takeaway

The average revenue per procedure and gross margins offer substantial operating leverage potential. That potential remains unproven until procedure volumes rise faster than sales and marketing expenditures.

## Competitive Landscape & Moat

### Competitive Landscape

A consistent market-share figure is not available for direct competitors and relevant conventional alternatives.

| Competitor | Market Share | Positioning | Advantages vs. Company | Disadvantages vs. Company | Current Direction |
|---|---|---|---|---|---|
| Globus Medical | Not comparable | Direct/substitute: spine implants and enabling technology | Broad portfolio, hospital access, established surgeon relationships, robotics and navigation | Less focused on patient-specific implant manufacturing | Established incumbent |
| Medtronic | Not comparable | Direct/substitute: spine implants and surgical planning | Scale, distribution, R&D resources and integrated surgical solutions | Personalized implants are not its central business focus | Established incumbent |
| DeGen Medical | Not disclosed | Direct segment: personalized spine implants | Competing patient-specific technology and product development | Commercial scale and clinical evidence are less transparent | Entering personalized segment |
| Johnson & Johnson / DePuy Synthes | Not comparable | Conventional spine-implant substitute; not patient-specific equivalence | Established implant franchise and purchasing relationships | Larger, more diversified product priorities | Established incumbent |

### Moat Assessment

Carlsmed has three possible competitive advantages: specialized manufacturing know-how, an integrated planning-to-implant workflow, and accumulated clinical data.

Its most persuasive clinical evidence is a published retrospective comparison involving 115 aprevo-treated patients and 997 patients in a conventional-implant comparator cohort. Two-year mechanical complication-related reoperation rates were 4.3% versus 16.6%, a 74% relative reduction.

That is clinically meaningful if the advantage is reproducible. However, it was not a randomized head-to-head trial. Differences in patient selection, surgical practice, and other variables could affect results. A broader prospective evidence base will be important for sustaining premium positioning.

Competition in personalized implants is also no longer hypothetical. DeGen Medical has obtained FDA 510(k) clearance for a patient-specific implant system, and Carlsmed filed a patent infringement complaint against the company in September 2026. The lawsuit contains allegations, not an established finding of infringement. Its existence underscores both the possible value and the contested nature of Carlsmed's intellectual property.

Carlsmed's FDA clearances and Breakthrough Device designation can help commercialization, but Breakthrough designation does not itself establish superior outcomes.

**Moat direction: Developing, not yet durable.**

### Competitive Takeaway

The business has differentiated capabilities, but switching costs, clinical superiority across broad patient groups, and protection from large competitors still need to be established.

## Financial Profile

### Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

| Period | Revenue | Growth | Gross Margin | Operating Margin | FCF | FCF Margin | SBC | Diluted Shares | Cash | Debt |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| FY2024 | $27.2M | — | 73.8% | -88.8% | ~-$25.7M | ~-94.6% | $0.3M | 4.1M | $40.2M | ~$15.6M |
| FY2025 | $50.5M | +86% | 75.3% | -60.5% | ~-$30.3M | ~-60.0% | $1.9M | 14.2M | $109.9M | ~$15.6M |
| Q1 FY2026 | $16.116 | N/D | 77.1% | -57.6% | −$13.086 (derived: CFO - capex) | -81.2% | $1.629 | 26.836 | $73.016 | N/D |
| Q2 FY2026 | $18.94 | N/D | 76.8% | -58.3% | −$7.479 (derived: current YTD - prior YTD) | -39.5% | $2.271 (derived: current YTD - prior YTD) | 27.191 | $46.244 | N/D |
| H1 FY2026 | $35.056 | N/D | 76.9% | -57.9% | −$20.565 (derived: CFO - capex) | -58.7% | $3.9 | 27.004 | $46.244 | N/D |

#### Supplemental historical reporting context (retained)

#### Supplemental historical reporting context (retained)

#### Supplemental historical reporting context (retained)

The weighted-average share figures are distorted by the 2025 IPO and conversion of preferred stock. They should not be interpreted as comparable organic dilution rates.

### Financial Takeaways

There are two opposing trends.

Revenue nearly doubled in 2025 and increased another 57% in the first six months of 2026. Gross margins also improved steadily. These figures suggest the company is scaling production effectively.

But operating losses remain substantial. Q2 2026 operating loss increased to approximately $11.0 million from $6.5 million a year earlier, as investment in commercial expansion, development and administration exceeded the incremental gross profit. The gross-margin improvement has not yet translated into sustained operating leverage.

**Liquidity and Dilution.** At June 30, Carlsmed held approximately $89.3 million in cash and investments against around $15.6 million of term-loan principal. Its operating cash burn was $20.4 million in the first half.

At that rate, cash and investments represented roughly two years of operating burn, before capital investment, changes in spending, debt obligations, and future financing. That is a cushion, but not an invitation to ignore financing risk.

Stock-based compensation also increased to $3.9 million in H1 2026, equivalent to roughly 11% of revenue. The growing pool of options and share awards should be included in any long-term per-share forecast. Additional financing could increase dilution further if losses persist.

**Financial direction: Mixed.** Revenue growth, pricing economics and gross margin are improving, but operating losses, cash burn and SBC remain material concerns.

## Management & Capital Allocation

Founder and CEO Mike Cordonnier has positioned Carlsmed as a differentiated technology business rather than a conventional implant supplier. Commercial execution has been encouraging, particularly the expansion into cervical surgery, improving manufacturing lead times, and strong surgeon adoption.

The company is also investing heavily in sales expansion and new products, an understandable strategy in a market where surgeon loyalty and hospital access matter.

The management team changed recently. Richard Heppenstall was appointed CFO in September, replacing Leo Greenstein, and Tony Jarc became Chief Product and AI Officer in October. The company reaffirmed 2026 revenue guidance when announcing the CFO transition.

The new CFO's ability to balance commercial investment against cash burn is a key near-term test. At the same time, equity awards and the broader compensation structure require monitoring because per-share value creation—not just revenue growth—must ultimately determine investment success.

### Management Takeaway

Execution on product adoption is promising, but capital allocation has not yet demonstrated that high growth can lead to profitable growth.

## Valuation

### Current Valuation

| Metric | Value |
|---|---:|
| Price Snapshot | $14.40 — 2026-11-03 regular-session close, America/New_York |
| Market Capitalization | $366.1M |
| Enterprise Value | $298.8M |
| Trailing revenue | $63.3M |
| EV / trailing revenue | 4.72× |
| EV / 2026 guidance midpoint | 3.93× |
| GAAP P/E | Not meaningful |
| FCF yield | Negative |

Carlsmed looks inexpensive relative to the growth rates usually associated with early-stage medtech companies. But the enterprise valuation is not especially low compared with profitable, established spinal-device peers.

Only the price row is refreshed here. Other quoted valuation statistics retain their earlier source dates and definitions.

### Comparable Company Analysis

| Company | Relevance | Public / Private | EV / Sales | Additional Valuation Metric | Growth / Margin / Risk Context |
|---|---|---|---:|---:|---|
| **Carlsmed** | Subject | Public | **4.72×** | 3.93× EV / 2026 guidance sales | ~57% H1 growth; loss-making |
| Globus Medical | Direct spine competitor | Public | 3.04× | N/A | Profitable and diversified spine platform |
| DeGen Medical | Direct personalized-implant competitor | Private | N/A — private | N/A — private | Commercial scale not disclosed |
| Medtronic | Secondary valuation anchor | Public | 3.60× | N/A | Highly diversified, profitable medtech |

**Comparable takeaway:** The premium to Globus may be warranted if Carlsmed can sustain much higher revenue growth and approach profitability. But today's valuation already assumes it will develop a competitive advantage stronger than currently demonstrated. DeGen is a closer product competitor but lacks public-market valuation data; Medtronic is a secondary diversified valuation anchor.

### Valuation Scenarios

I use a three-year revenue-multiple framework to estimate a value as of October 2026. These are analyst assumptions, not management projections.

The estimated value is the discounted 2029 enterprise value plus terminal net cash, divided by assumed future diluted shares. I use a 15% annual discount rate because of the company's execution, cash-burn and competitive risks.

| Scenario | Key Assumptions | Fair Value | Probability | Probability Rationale | Return From Price Snapshot |
|---|---|---:|---:|---|---:|
| **Bear** | $110M 2029 revenue, 2× EV/sales, 32M shares, no net cash | $4.52 | 30% | Slower adoption, competition, continued losses and dilution | -68.6% |
| **Base** | $185M 2029 revenue, 4× EV/sales, 31M shares, $25M net cash | $16.23 | 50% | Continued surgeon adoption, hospital access and growth in product applications | +12.7% |
| **Bull** | $270M 2029 revenue, 6× EV/sales, 32M shares, $40M net cash | $34.11 | 20% | Platform leadership, sustained faster growth and premium multiple | +136.9% |
| **Probability-Weighted** | Weighted fair value across scenarios | **$16.29** | **100%** |  | +13.1% |

The base case assumes revenue rises from approximately $76 million in 2026 to $185 million in 2029, representing about 35% annualized growth. That requires continued surgeon adoption, additional hospital access, and meaningful growth in cervical and newer lumbar applications.

The bull case assumes Carlsmed establishes a leading platform position, sustains higher growth, and earns a premium valuation. A 6× terminal sales multiple would be difficult to justify without convincing evidence of durable competitive strength and progress toward attractive operating margins.

The bear case reflects slower growth, competition from personalized and conventional solutions, lower investor willingness to fund losses, and dilution. It is not a hard downside floor.

### Valuation Takeaway

- **Primary valuation method:** Discounted 2029 revenue multiples with share-count and net-cash assumptions.
- **Cross-check methods:** EV / trailing revenue; EV / 2026 guidance sales; Globus Medical and Medtronic multiples.
- **Key valuation dependencies:** Revenue trajectory, surgeon and hospital adoption, competition, reimbursement, operating leverage and dilution.
- **Valuation confidence / Risk Level:** High uncertainty / High risk.
- **Margin-of-safety conclusion:** The probability-weighted value of $16.29 gives approximately 21.5% upside, but the -66.3% modeled bear outcome makes the risk/reward distribution highly asymmetric.

I would require more than a modest discount to modeled fair value before buying such a business. This is why the valuation framework produces a **Hold / Watch**, despite strong reported revenue growth.

The purchase zones from the repository's risk-aware methodology are:

| Zone | Share Price |
|---|---:|
| Strong Buy | ≤ $4.97 |
| Buy | $4.98–$13.03 |
| Hold / Watch | $13.04–$18.10 |
| Avoid | Above $18.10 |

These are model-derived thresholds, not expected trading levels or a claim that the company would be fundamentally sound if its share price collapsed.

## Analyst Questions

The August 5, 2026 earnings call included five substantive analyst participants. Their questions are particularly useful because they identify where management's confidence is not yet supported by disclosed numbers.

| Analyst / Firm | Core Question | Management Response | Research Read-Through |
|---|---|---|---|
| Matthew O'Brien / Piper Sandler | Why does H2 guidance imply slower growth than H1? What is driving new surgeon additions? | Guidance is intentionally prudent; management cited strong surgeon interest across lumbar and cervical. | No admission of deteriorating demand, but surgeon conversion and utilization warrant monitoring. |
| Aidan for Travis Steed / Bank of America | Will Medicare reimbursement affect 2026 demand? Is the benefit price or procedure volume? | Management expects little material 2026 benefit; hospital access and volume matter more than higher selling prices. | The catalyst is mainly for 2027 onward, and its timing remains uncertain. |
| Richard Newitter / Truist | Why might Q3 decline sequentially? How high can gross margins go? | Guidance excludes meaningful incremental reimbursement revenue. Margins could approach the low 80s over time, but this is not formal guidance. | Long-term margins could be excellent, but the near-term growth cadence deserves scrutiny. |
| Izzy for Ryan Zimmerman / U.S. Bancorp | What is the corra rollout plan, and how should investors think about emerging custom-implant competitors? | Management planned broad commercialization after evaluation and emphasized platform differentiation. | Competition was not quantified or directly rebutted; this is an unresolved risk. |
| David Saxon / Needham | How large will cervical become, what are procedure prices, and are reimbursement discussions beginning? | Cervical could be 11–12% of H2 revenue; average lumbar/cervical pricing is roughly $29k/$18k; hospital conversations are expanding. | Cross-selling is promising, but full commercialization and access take time. |

### Analyst-Q&A Takeaway

The most significant unanswered question is not whether Carlsmed can keep growing. Its recent results support that. It is **how quickly growth can translate into positive operating cash flow**, particularly when commercial spending remains unusually high relative to revenue.

Management's responses favor a volume-led growth thesis, but they provide insufficient visibility on surgeon utilization, competitive penetration, and the timing of operating breakeven.

## Thesis Monitoring

| Driver | Current State | Positive Trigger / Catalyst | Negative Trigger / Falsifier | What It Changes |
|---|---|---|---|---|
| Revenue growth | +57% Q2 YoY | Sustained 40%+ growth | Growth falls below 25% without clear explanation | Growth forecast and multiples |
| Surgeon adoption | Trained users +60% YoY | Higher cases per surgeon | Growth depends only on recruiting new surgeons | Retention and lifetime economics |
| Medicare reimbursement | Effective Oct 1, 2026 | Meaningful 2027 hospital access expansion | Limited adoption despite improved reimbursement | Volume and addressable market |
| Cervical expansion | ~10% Q2 revenue | Higher volume and successful corra launch | Weak surgeon demand or delayed launches | Cross-selling and revenue per case |
| Clinical evidence | Encouraging retrospective results | Robust prospective outcomes | Efficacy advantage fails to replicate | Moat and pricing |
| Gross margin | 76.8% in Q2 | Sustained high-70% margin | Manufacturing costs or discounts pressure margin | Long-run operating leverage |
| Operating leverage | Losses and cash burn remain high | S&M falls materially as % of revenue | Continued operating losses grow despite scale | Profitability and financing |
| Competition / IP | DeGen active; litigation filed | Stronger differentiation and IP protection | Patent losses or equivalent rival offerings | Market share and moat |
| Capital needs | ~$89M cash and investments | Longer runway through reduced burn | Dilutive financing before profitability | Per-share value and risk |

The next earnings report is estimated for early November 2026, though the date should be confirmed through investor relations. Over a longer horizon, prospective clinical evidence and the extent of the 2027 reimbursement benefit will be more important than any single quarterly revenue beat.

## Quality & Opportunity Scorecards

### Quality Score

| Component | Score | Weight | Weighted Contribution | Evidence |
|---|---:|---:|---:|---|
| Business durability and economics | 65 | 25% | 16.3 | High implant gross margins; long-term procedure repeat economics not yet established |
| Moat and competitive position | 58 | 25% | 14.5 | Differentiated planning/manufacturing; larger rivals and emerging custom-implant competitors |
| Growth runway and durability | 90 | 20% | 18.0 | Large addressable procedure market and strong adoption growth |
| Financial quality and balance sheet | 47 | 15% | 7.1 | High cash burn, continued losses, dilution; IPO cash cushion |
| Management, governance and capital allocation | 60 | 15% | 9.0 | Product execution positive; profitability and allocation track record unproven |
| **Quality Score** | **64.8** | **100%** | **64.8** | **Tier C** |

- **Quality Tier:** C.
- **Speculative override:** None.

### Opportunity Score

| Component | Raw Input | Normalized Score | Weight | Weighted Contribution |
|---|---|---|---|---|
| Quality | 64.8 | 64.8 | 30% | 19.4 |
| Probability-weighted upside | +13.1% | 76.2 | 35% | 26.7 |
| Bear-case downside | -68.6% | 0.0 | 20% | 0.0 |
| Risk / valuation confidence | 37 | 37.0 | 15% | 5.6 |
| **Opportunity Score** |  | **51.7** | **100%** | **51.7** |

- **Opportunity Rank:** #41 of 76
- **Zone Status:** Hold / Watch

## Portfolio Context

- **Tracking tier:** On the Radar.
- **Owned:** No position recorded in the repository portfolio ledger.
- **Tracking source of truth:** ontheradar.md.
- **Portfolio source of truth:** portfolio/holdings.md.
- **Scoring independence:** Ownership, account, share count, position size, and cost basis do not alter Quality Score, Opportunity Score, rank, rating, valuation, or valuation zones.

CARL was not previously listed in the Investing repository's primary or secondary watchlist. No shares are recorded, and no shared ranking has been assigned.

## Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale |
|---|---:|---|---|---|---|---|---:|---:|---:|---:|---|---|
| 2026-10-17 (price snapshot 2026-10-16) | $13.41 | Hold / Watch | Hold / Watch | $4.98–$13.03 | ≤ $4.97 | > $18.10 | $16.23 | $16.29 | +21.5% | 64.8 / C | 57.5 / Unassigned | Initial analysis; approved addition to On the Radar on 2026-10-21 |
| 2026-10-21 (America/New_York) | $14.18 | Hold / Watch | Hold / Watch | >$4.97–$13.03 | ≤ $4.97 | > $18.10 | $16.23 | $16.29 | +14.9% | 64.8 | 52.9 / #32 | Common close and shared-universe rank; prior fundamental assumptions and zones preserved |

#### Final Assessment

Carlsmed is worth following. The personalized surgery platform is differentiated, the clinical data are promising, and improving reimbursement could help accelerate adoption.

I am less confident that it will build a lasting competitive advantage and generate enough cash flow to justify a substantial premium over established medtech peers.

At the current valuation, the market appears to be pricing in continued strong growth without offering enough downside protection.

**My recommendation is Hold / Watch, with a high-risk classification.** I would revisit the view if operating leverage becomes visible, stronger clinical evidence validates the product's advantages, or the stock offers a more compelling margin of safety.

---

## Material Sources

| Source | Type | Date / Period | What It Supports |
|---|---|---|---|
| [Carlsmed Q2 2026 Financial Results](https://investors.carlsmed.com/news-releases/news-release-details/carlsmedr-reports-second-quarter-2026-financial-results-and) | Company IR | 2026-08-05 | Earnings, guidance, surgeon adoption, reimbursement |
| [2026 Q2 Form 10-Q](https://www.sec.gov/Archives/edgar/data/1794546/000179454626000016/carl-20260630.htm) | Regulatory filing | H1 2026 | Cash flow, SBC, shares, debt, business risks |
| [2025 Form 10-K](https://www.sec.gov/Archives/edgar/data/1794546/000119312526071551/carl-20251231.htm) | Regulatory filing | FY 2025 | Business model, financial history, TAM, revenue recognition |
| [Q2 2026 Earnings Call](https://stockanalysis.com/stocks/carl/transcripts/660995-q2-2026/) | Transcript | 2026-08-05 | Management commentary and material analyst Q&A |
| [Clinical Study Announcement](https://investors.carlsmed.com/news-releases/news-release-details/carlsmed-aprevor-lumbar-2-year-data-published-global-spine) | Company IR / Clinical study | 2026-01-06 | Retrospective patient outcomes evidence |
| [Bi-lateral Posterior System Launch](https://investors.carlsmed.com/news-releases/news-release-details/carlsmed-launches-aprevor-lumbar-bi-lateral-posterior-system) | Company IR | 2026-10-14 | Recent product commercialization |
| [CFO Appointment and Guidance Reaffirmation](https://www.globenewswire.com/news-release/2026/09/28/3369860/0/en/carlsmed-appoints-richard-heppenstall-as-chief-financial-officer.html) | Company announcement | 2026-09-28 | Management changes and outlook |
| [Carlsmed–DeGen Lawsuit](https://investors.carlsmed.com/news-releases/news-release-details/carlsmed-inc-files-patent-infringement-lawsuit-against-degen) | Company IR | 2026-09-15 | Competitive and IP risk |
| [FDA DeGen 510(k) Record](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K251829) | Regulatory filing | 2025-12-08 | Competing patient-specific implant clearance |
| [CARL market valuation](https://stockanalysis.com/stocks/carl/statistics/) | Market data | 2026-10-16 snapshot | Price, market capitalization, CARL valuation |
| [GMED market valuation](https://stockanalysis.com/stocks/gmed/statistics/) | Market data | 2026-10-16 snapshot | Globus Medical multiple |
| [MDT market valuation](https://stockanalysis.com/stocks/mdt/statistics/) | Market data | 2026-10-16 snapshot | Medtronic multiple |
| [CARL common regular-close snapshot](https://stockanalysis.com/stocks/carl/history/) | Market data | 2026-10-20 16:00 EDT | Refreshed price, scenario returns and normalized Opportunity Score / shared rank |
| [SEC XBRL company facts — CARL](https://data.sec.gov/api/xbrl/companyfacts/CIK0001794546.json) | Regulatory filing (as tagged) | FY2026, through 2026-06-30 | Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics |